Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder often diagnosed in school-age children that frequently persists into adulthood.Pharmacologic treatment of ADHD…
Med Lett Drugs Ther. 2025 Sep 1; 67(1736):137-44 doi:10.58347/tml.2025.1736a
Attention-deficit/hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder often diagnosed in school-age children that frequently persists into adulthood.Pharmacologic treatment of ADHD has been associated with reduced risks of substance abuse, criminal behavior, unintentional injuries, serious traffic accidents, and all-cause mortality. Drugs approved by the FDA for treatment of ADHD are listed in Table 1.
The FDA has approved a long-acting fixed-dose combination of the stimulant dexmethylphenidate and the prodrug serdexmethylphenidate ( Azstarys – Corium) for once-daily treatment of…
Med Lett Drugs Ther. 2021 Oct 4; 63(1634):157-9
The FDA has approved a long-acting fixed-dose combination of the stimulant dexmethylphenidate and the prodrug serdexmethylphenidate ( Azstarys – Corium) for once-daily treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥6 years old. Azstarys is the first product containing serdexmethylphenidate to become available in the US.
The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain…
Med Lett Drugs Ther. 2015 Jul 20; 57(1473):101-3
The FDA has approved Aptensio XR (Rhodes), an extended-release formulation of methylphenidate hydrochloride, for treatment of attention-deficit/hyperactivity disorder (ADHD). The Aptensio XR capsules contain multilayer beads designed to provide both a rapid onset and a long duration of action. This formulation of methylphenidate has been available in Canada as Biphentin since 2006.
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that has been diagnosed in up to 10% of school-age children in the US, most often in boys, and frequently persists into…
Med Lett Drugs Ther. 2015 Mar 16; 57(1464):37-40
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that has been diagnosed in up to 10% of school-age children in the US, most often in boys, and frequently persists into adulthood. A recent study in a large Danish cohort found that ADHD was associated with increased mortality in children, adolescents, and adults, mainly due to accidents. Pharmacologic treatment of ADHD has been reported to lower the risk of serious traffic accidents and criminal behavior.
Lisdexamfetamine dimesylate (Vyvanse) , a prodrug of dextroamphetamine previously approved for treatment of attention-deficit/hyperactivity disorder, has now been approved for treatment of moderate-to-severe…
The FDA has approved a once-daily, extended-release oral suspension of methylphenidate ( Quillivant XR – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first liquid…
Med Lett Drugs Ther. 2013 Feb 4; 55(1409):10-1
The FDA has approved a once-daily, extended-release oral suspension of methylphenidate ( Quillivant XR – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first liquid formulation of the drug to be marketed for once-daily use. A short-acting oral solution ( Methylin , and generics) has been available since 2003.
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in about 5% of school-age children, most often in boys, and frequently persists into young adulthood.
Treat Guidel Med Lett. 2011 May; 9(105):23-8
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in about 5% of school-age children, most often in boys, and frequently persists into young adulthood.
The FDA has approved an extended-release formulation of clonidine hydrochloride ( Kapvay – Shionogi) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. It is the…
Med Lett Drugs Ther. 2011 Feb 7; 53(1357):10-2
The FDA has approved an extended-release formulation of clonidine hydrochloride ( Kapvay – Shionogi) for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-17 years old. It is the second alpha 2 -adrenergic agonist approved for this indication; guanfacine hydrochloride (Intuniv) was the first, but only clonidine is approved for use with stimulants.
Short-acting methylphenidate (MPH) is effective for treatment of attention-deficit/hyperactivity disorder (ADHD), but its 3-5 hour duration of action usually requires mid-day dosing in school, which children…
Med Lett Drugs Ther. 2009 Mar 23; 51(1308):22-4
Short-acting methylphenidate (MPH) is effective for treatment of attention-deficit/hyperactivity disorder (ADHD), but its 3-5 hour duration of action usually requires mid-day dosing in school, which children may find disruptive or stigmatizing.
The American Heart Association (AHA) recently published a statement saying that it would be reasonable to obtain an electrocardiogram (ECG) in children being evaluated for stimulant drug therapy for attention…
Med Lett Drugs Ther. 2008 Jul 28; 50(1291):60
The American Heart Association (AHA) recently published a statement saying that it would be reasonable to obtain an electrocardiogram (ECG) in children being evaluated for stimulant drug therapy for attention deficit hyperactivity disorder (ADHD). A subsequent news release in conjunction with the American Academy of Pediatrics provided a clarification, saying that it would be reasonable to consider obtaining an ECG in such children.
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in 5-7% of school-age children and has also been estimated to occur in about 4% of adults. ADHD is characterized by…
Treat Guidel Med Lett. 2006 Nov; 4(51):77-82
Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that occurs in 5-7% of school-age children and has also been estimated to occur in about 4% of adults. ADHD is characterized by a persistent pattern of frequent, severe inattention and/or hyperactivity/impulsivity that starts before the age of 7, is present in 2 or more settings (such as home and school), causes significant impairment in function, and is not caused by another mental disorder. The drugs approved for treatment of ADHD by the FDA are listed in this article. Except for atomoxetine, they are all stimulants and are classified as controlled substances by the US Drug Enforcement Administration (DEA).
Atomoxetine ( Strattera - Lilly), a nonstimulant drug that is not a controlled substance, was approved by the FDA in early 2003 for the treatment of attention deficit hyperactivity disorder (ADHD). At that…
Med Lett Drugs Ther. 2004 Aug 16; 46(1189):65
Atomoxetine ( Strattera - Lilly), a nonstimulant drug that is not a controlled substance, was approved by the FDA in early 2003 for the treatment of attention deficit hyperactivity disorder (ADHD). At that time, The Medical Letter concluded that it was unclear whether atomoxetine was as effective as stimulants such as methylphenidate ( Concerta , and others) ( Medical Letter 2003; 45:11 ). Since then, the drug has been heavily advertised directly to the public for use in both children and adults.
With the 2004 Olympics only weeks away, performance-enhancing drugs will once again be receiving a great deal of attention. The US Anti-Doping Agency has published a list of drugs banned in Olympic sports (…
Med Lett Drugs Ther. 2004 Jul 19; 46(1187):57-9
With the 2004 Olympics only weeks away, performance-enhancing drugs will once again be receiving a great deal of attention. The US Anti-Doping Agency has published a list of drugs banned in Olympic sports ( www.usantidoping.org ) that includes, at least for some sports, all but 2 of the drugs reviewed here.